Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
Volume 0.81M
Average 0.40M
ABOS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Acumen Pharmaceuticals, Inc.NASDAQ: ABOS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $16.48M fell 34.8% year over year, behind the -9.9% change in trailing-twelve-month research & development. Sequentially, it fell 19.7% from the prior quarter. Over 3 fiscal years it compounded at +48.0% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -34.8% toward the trailing-twelve-month pace of -9.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 104.89M USD
- Year-over-year change
- +11.8%
- 4-year CAGR
- +70.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.89M | +11.8% |
| FY2024 | 2024-12-31 | 93.8M | +121.7% |
| FY2023 | 2023-12-31 | 42.32M | +30.8% |
| FY2022 | 2022-12-31 | 32.36M | +163.0% |
| FY2021 | 2021-12-31 | 12.31M | — |
Research & Development vs competitors
How ABOS compares with its peers on the latest reported figures
- ABOS's LTM Mar 2026 research & development of $96.1M is the 3rd highest of the 10 companies compared; the peer median is $38.53M.
- Its year-over-year change of -9.9% is the 2nd highest of 10, against a peer median of -33.6%.
- Over three fiscal years its annual growth of +48.0% compares with a peer median of -15.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $114.68M | -37.7% | -16.4% | 622.7% | |
| LTM Mar 2026 | $100.48M | -23.9% | -30.4% | 1590.8% | |
| LTM Mar 2026 | $96.1M | -9.9% | +48.0% | — | |
| LTM Mar 2026 | $51.51M | -27.2% | -33.9% | — | |
| LTM Mar 2026 | $41.33M | -11.2% | -6.2% | 274.8% | |
| LTM Mar 2026 | $38.53M | -58.1% | — | 31.1% | |
| LTM Mar 2026 | $37.82M | -33.6% | -23.5% | 3297.1% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $33.44M | +11.2% | +29.0% | 279.0% |
| LTM Mar 2026 | $27.77M | -70.1% | -6.9% | 50.7% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $9.64M | -35.9% | -14.4% | — |
| Peer median (excluding ABOS) | $38.53M | -33.6% | -15.4% | 279.0% | |
Competitors are the stored peer set for ABOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 12.31M | 0 | 0 | 0 | 0 |
| Gross Profit | (12.31M) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 12.31M | 32.36M | 42.32M | 93.8M | 104.89M |
| Selling, General & Admin | 7.28M | 12.88M | 18.82M | 20.22M | 18.95M |
| Operating Expenses | 7.28M | 45.24M | 61.14M | 114.02M | 123.83M |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | 184K |
| EBITDA | (100.6M) | (42.69M) | (51.61M) | (98.08M) | (116.93M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (19.58M) | (45.24M) | (61.14M) | (114.02M) | (123.83M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 84K | 2.39M | 10.79M | 14.32M | 7.45M |
| Interest Expense | 0 | 0 | 581K | 4.07M | 4.22M |
| Other Income / Expenses | (81.02M) | 2.38M | 8.77M | 11.69M | 2.5M |
| Income Before Tax | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| EPS (Diluted) | (2.63) | (1.06) | (1.08) | (1.71) | (2.00) |
| Weighted Avg Shares | 38.27M | 40.6M | 48.49M | 60.01M | 60.56M |
| Weighted Avg Shares (Diluted) | 38.27M | 40.6M | 48.61M | 60.01M | 60.56M |
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
Intrinsic Alpha fair value
Locked
Current Price
$2.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.